141 related articles for article (PubMed ID: 14634050)
1. D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor.
Jarrahian A; Watts VJ; Barker EL
J Pharmacol Exp Ther; 2004 Mar; 308(3):880-6. PubMed ID: 14634050
[TBL] [Abstract][Full Text] [Related]
2. D2 dopamine receptor-induced sensitization of adenylyl cyclase type 1 is G alpha(s) independent.
Vortherms TA; Nguyen CH; Bastepe M; Jüppner H; Watts VJ
Neuropharmacology; 2006 Apr; 50(5):576-84. PubMed ID: 16376953
[TBL] [Abstract][Full Text] [Related]
3. Heterologous sensitization of recombinant adenylate cyclases by activation of D(2) dopamine receptors.
Cumbay MG; Watts VJ
J Pharmacol Exp Ther; 2001 Jun; 297(3):1201-9. PubMed ID: 11356947
[TBL] [Abstract][Full Text] [Related]
4. Using molecular tools to dissect the role of Galphas in sensitization of AC1.
Vortherms TA; Nguyen CH; Berlot CH; Watts VJ
Mol Pharmacol; 2004 Dec; 66(6):1617-24. PubMed ID: 15361543
[TBL] [Abstract][Full Text] [Related]
5. Sensitization of neuronal A2A adenosine receptors after persistent D2 dopamine receptor activation.
Vortherms TA; Watts VJ
J Pharmacol Exp Ther; 2004 Jan; 308(1):221-7. PubMed ID: 14566008
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of adenylate cyclase by Galpha i/o-coupled receptors.
Watts VJ; Neve KA
Pharmacol Ther; 2005 Jun; 106(3):405-21. PubMed ID: 15922020
[TBL] [Abstract][Full Text] [Related]
7. Novel regulatory properties of human type 9 adenylate cyclase.
Cumbay MG; Watts VJ
J Pharmacol Exp Ther; 2004 Jul; 310(1):108-15. PubMed ID: 14996950
[TBL] [Abstract][Full Text] [Related]
8. Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.
Marcellino D; Carriba P; Filip M; Borgkvist A; Frankowska M; Bellido I; Tanganelli S; Müller CE; Fisone G; Lluis C; Agnati LF; Franco R; Fuxe K
Neuropharmacology; 2008 Apr; 54(5):815-23. PubMed ID: 18262573
[TBL] [Abstract][Full Text] [Related]
9. Short- and long-term regulation of adenylyl cyclase activity by delta-opioid receptor are mediated by Galphai2 in neuroblastoma N2A cells.
Zhang L; Tetrault J; Wang W; Loh HH; Law PY
Mol Pharmacol; 2006 Jun; 69(6):1810-9. PubMed ID: 16525132
[TBL] [Abstract][Full Text] [Related]
10. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors enhances heterodimer formation: a mechanism for receptor cross-talk?
Kearn CS; Blake-Palmer K; Daniel E; Mackie K; Glass M
Mol Pharmacol; 2005 May; 67(5):1697-704. PubMed ID: 15710746
[TBL] [Abstract][Full Text] [Related]
11. D2 dopamine receptor activation of potassium channels is selectively decoupled by Galpha-specific GoLoco motif peptides.
Webb CK; McCudden CR; Willard FS; Kimple RJ; Siderovski DP; Oxford GS
J Neurochem; 2005 Mar; 92(6):1408-18. PubMed ID: 15748159
[TBL] [Abstract][Full Text] [Related]
12. G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors.
Lane JR; Powney B; Wise A; Rees S; Milligan G
J Pharmacol Exp Ther; 2008 Apr; 325(1):319-30. PubMed ID: 18218829
[TBL] [Abstract][Full Text] [Related]
13. Subchronic haloperidol increases CB(1) receptor binding and G protein coupling in discrete regions of the basal ganglia.
Andersson M; Terasmaa A; Fuxe K; Strömberg I
J Neurosci Res; 2005 Oct; 82(2):264-72. PubMed ID: 16175569
[TBL] [Abstract][Full Text] [Related]
14. Differential effects of regulator of G protein signaling (RGS) proteins on serotonin 5-HT1A, 5-HT2A, and dopamine D2 receptor-mediated signaling and adenylyl cyclase activity.
Ghavami A; Hunt RA; Olsen MA; Zhang J; Smith DL; Kalgaonkar S; Rahman Z; Young KH
Cell Signal; 2004 Jun; 16(6):711-21. PubMed ID: 15093612
[TBL] [Abstract][Full Text] [Related]
15. Dopamine D2L receptor couples to G alpha i2 and G alpha i3 but not G alpha i1, leading to the inhibition of adenylate cyclase in transfected cell lines.
O'Hara CM; Tang L; Taussig R; Todd RD; O'Malley KL
J Pharmacol Exp Ther; 1996 Jul; 278(1):354-60. PubMed ID: 8764370
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human cannabinoid CB2 receptor coupled to chimeric Galpha(qi5) and Galpha(qo5) proteins.
Malysz J; Daza AV; Kage K; Grayson GK; Yao BB; Meyer MD; Gopalakrishnan M
Eur J Pharmacol; 2009 Jan; 603(1-3):12-21. PubMed ID: 19071106
[TBL] [Abstract][Full Text] [Related]
17. A highly conserved glycine within linker I and the extreme C terminus of G protein alpha subunits interact cooperatively in switching G protein-coupled receptor-to-effector specificity.
Kostenis E; Martini L; Ellis J; Waldhoer M; Heydorn A; Rosenkilde MM; Norregaard PK; Jorgensen R; Whistler JL; Milligan G
J Pharmacol Exp Ther; 2005 Apr; 313(1):78-87. PubMed ID: 15615862
[TBL] [Abstract][Full Text] [Related]
18. Galphaq-coupled receptor signaling enhances adenylate cyclase type 6 activation.
Beazely MA; Watts VJ
Biochem Pharmacol; 2005 Jul; 70(1):113-20. PubMed ID: 15885660
[TBL] [Abstract][Full Text] [Related]
19. Cannabinoid signalling.
Demuth DG; Molleman A
Life Sci; 2006 Jan; 78(6):549-63. PubMed ID: 16109430
[TBL] [Abstract][Full Text] [Related]
20. Molecular dissection of G protein preference using Gsalpha chimeras reveals novel ligand signaling of GPCRs.
Hsu SH; Luo CW
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E1021-9. PubMed ID: 17652154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
